Dabigatran improves efficiency of an elective direct current cardioversion service

W. K. Choo, S. Fraser, G. Padfield, G. Rushworth, C. Bloe, P. Forsyth, S. Cross, S. J. Leslie

Research output: Contribution to journalAbstract

Abstract

Anticoagulation prior to direct current cardioversion (DCCV) is mandatory to reduce the risk of thromboembolism. We examined the impact of the use of dabigatran as an alternative to warfarin on the efficiency of an outpatient DCCV service. A total of 242 DCCVs performed on 193 patients over a 36-month period were analysed. Patients were divided into two cohorts; cohort A included cases in the 22-month period before the introduction of dabigatran and cohort B included cases in the 14-month period after the introduction of dabigatran. All patients in cohort A received warfarin. In cohort B, 48.4% received dabigatran. A larger number of patients from cohort A were rescheduled due to subtherapeutic international normalised ratios (INRs) compared with cohort B (42.1% vs. 15.6%, p<0.001). Those who received dabigatran had significantly lower rates of rescheduling compared with those who received warfarin (9.7% vs. 34.4%, p<0.001). The length of time between initial assessment and DCCV was 24 days shorter in cohort B than cohort A (p<0.001) and 22 days shorter with those who took dabigatran than warfarin (p=0.0015). Outcomes in achieving and maintaining sinus rhythm were comparable in both cohorts and anticoagulants (all p>0.05). This study demonstrates that the use of dabigatran can improve the efficiency of an elective DCCV service
Original languageEnglish
Article numberP6221
Pages (from-to)1102-1102
Number of pages1
JournalEuropean Heart Journal
Volume35
Issue numberSuppl. 1
Early online date4 Feb 2014
Publication statusPublished - 1 Sep 2014
EventCongress of the European-Society-of-Cardiology (ESC) 2014 - Barcelona, Spain
Duration: 30 Aug 20143 Sep 2014

Cite this

Choo, W. K., Fraser, S., Padfield, G., Rushworth, G., Bloe, C., Forsyth, P., ... Leslie, S. J. (2014). Dabigatran improves efficiency of an elective direct current cardioversion service. European Heart Journal, 35(Suppl. 1), 1102-1102. [P6221 ].

Dabigatran improves efficiency of an elective direct current cardioversion service. / Choo, W. K.; Fraser, S.; Padfield, G.; Rushworth, G.; Bloe, C.; Forsyth, P.; Cross, S.; Leslie, S. J.

In: European Heart Journal, Vol. 35, No. Suppl. 1, P6221 , 01.09.2014, p. 1102-1102.

Research output: Contribution to journalAbstract

Choo, WK, Fraser, S, Padfield, G, Rushworth, G, Bloe, C, Forsyth, P, Cross, S & Leslie, SJ 2014, 'Dabigatran improves efficiency of an elective direct current cardioversion service', European Heart Journal, vol. 35, no. Suppl. 1, P6221 , pp. 1102-1102.
Choo WK, Fraser S, Padfield G, Rushworth G, Bloe C, Forsyth P et al. Dabigatran improves efficiency of an elective direct current cardioversion service. European Heart Journal. 2014 Sep 1;35(Suppl. 1):1102-1102. P6221 .
Choo, W. K. ; Fraser, S. ; Padfield, G. ; Rushworth, G. ; Bloe, C. ; Forsyth, P. ; Cross, S. ; Leslie, S. J. / Dabigatran improves efficiency of an elective direct current cardioversion service. In: European Heart Journal. 2014 ; Vol. 35, No. Suppl. 1. pp. 1102-1102.
@article{b45596ed1f154b97826ec87175eacc2e,
title = "Dabigatran improves efficiency of an elective direct current cardioversion service",
abstract = "Anticoagulation prior to direct current cardioversion (DCCV) is mandatory to reduce the risk of thromboembolism. We examined the impact of the use of dabigatran as an alternative to warfarin on the efficiency of an outpatient DCCV service. A total of 242 DCCVs performed on 193 patients over a 36-month period were analysed. Patients were divided into two cohorts; cohort A included cases in the 22-month period before the introduction of dabigatran and cohort B included cases in the 14-month period after the introduction of dabigatran. All patients in cohort A received warfarin. In cohort B, 48.4{\%} received dabigatran. A larger number of patients from cohort A were rescheduled due to subtherapeutic international normalised ratios (INRs) compared with cohort B (42.1{\%} vs. 15.6{\%}, p<0.001). Those who received dabigatran had significantly lower rates of rescheduling compared with those who received warfarin (9.7{\%} vs. 34.4{\%}, p<0.001). The length of time between initial assessment and DCCV was 24 days shorter in cohort B than cohort A (p<0.001) and 22 days shorter with those who took dabigatran than warfarin (p=0.0015). Outcomes in achieving and maintaining sinus rhythm were comparable in both cohorts and anticoagulants (all p>0.05). This study demonstrates that the use of dabigatran can improve the efficiency of an elective DCCV service",
author = "Choo, {W. K.} and S. Fraser and G. Padfield and G. Rushworth and C. Bloe and P. Forsyth and S. Cross and Leslie, {S. J.}",
year = "2014",
month = "9",
day = "1",
language = "English",
volume = "35",
pages = "1102--1102",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "OXFORD UNIV PRESS",
number = "Suppl. 1",

}

TY - JOUR

T1 - Dabigatran improves efficiency of an elective direct current cardioversion service

AU - Choo, W. K.

AU - Fraser, S.

AU - Padfield, G.

AU - Rushworth, G.

AU - Bloe, C.

AU - Forsyth, P.

AU - Cross, S.

AU - Leslie, S. J.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Anticoagulation prior to direct current cardioversion (DCCV) is mandatory to reduce the risk of thromboembolism. We examined the impact of the use of dabigatran as an alternative to warfarin on the efficiency of an outpatient DCCV service. A total of 242 DCCVs performed on 193 patients over a 36-month period were analysed. Patients were divided into two cohorts; cohort A included cases in the 22-month period before the introduction of dabigatran and cohort B included cases in the 14-month period after the introduction of dabigatran. All patients in cohort A received warfarin. In cohort B, 48.4% received dabigatran. A larger number of patients from cohort A were rescheduled due to subtherapeutic international normalised ratios (INRs) compared with cohort B (42.1% vs. 15.6%, p<0.001). Those who received dabigatran had significantly lower rates of rescheduling compared with those who received warfarin (9.7% vs. 34.4%, p<0.001). The length of time between initial assessment and DCCV was 24 days shorter in cohort B than cohort A (p<0.001) and 22 days shorter with those who took dabigatran than warfarin (p=0.0015). Outcomes in achieving and maintaining sinus rhythm were comparable in both cohorts and anticoagulants (all p>0.05). This study demonstrates that the use of dabigatran can improve the efficiency of an elective DCCV service

AB - Anticoagulation prior to direct current cardioversion (DCCV) is mandatory to reduce the risk of thromboembolism. We examined the impact of the use of dabigatran as an alternative to warfarin on the efficiency of an outpatient DCCV service. A total of 242 DCCVs performed on 193 patients over a 36-month period were analysed. Patients were divided into two cohorts; cohort A included cases in the 22-month period before the introduction of dabigatran and cohort B included cases in the 14-month period after the introduction of dabigatran. All patients in cohort A received warfarin. In cohort B, 48.4% received dabigatran. A larger number of patients from cohort A were rescheduled due to subtherapeutic international normalised ratios (INRs) compared with cohort B (42.1% vs. 15.6%, p<0.001). Those who received dabigatran had significantly lower rates of rescheduling compared with those who received warfarin (9.7% vs. 34.4%, p<0.001). The length of time between initial assessment and DCCV was 24 days shorter in cohort B than cohort A (p<0.001) and 22 days shorter with those who took dabigatran than warfarin (p=0.0015). Outcomes in achieving and maintaining sinus rhythm were comparable in both cohorts and anticoagulants (all p>0.05). This study demonstrates that the use of dabigatran can improve the efficiency of an elective DCCV service

M3 - Abstract

VL - 35

SP - 1102

EP - 1102

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - Suppl. 1

M1 - P6221

ER -